Security
Bright Minds Biosciences Inc. · DRUG
DRUGCSECommon stockCurrentCIK 1827401Updated Oct 6, 2026
DRUG price & chart
Loading TradingView…
CSE:DRUG on TradingView ↗About the company
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2024 · CADSource
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossCAD | -2,801,946Source | -7,372,225Source | -14,964,941Source | -8,650,763Source |
| Additional Financial Items | ||||
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableCAD | 241,992Source | -1,197,254Source | 765,988Source | 506,150Source |
| AdjustmentsForSharebasedPaymentsCAD | 839,771Source | 1,152,131Source | 875,056Source | 880,615Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD | -10,126Source | 45,348Source | -258,824Source | -223,787Source |
| GeneralAndAdministrativeExpenseCAD | 264,009Source | 278,809Source | 478,248Source | 197,125Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD | 89,730Source | 86,112Source | 7,162Source | — |
| ProceedsFromIssuingSharesCAD | — | — | — | 27,744,826Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.26Source | 0.28Source | 0.27Source | 0.28Source |
| BasicEarningsLossPerShareCAD/shares | -0.65Source | -1.98Source | — | — |
| DepreciationRightofuseAssetsCAD | 73,357Source | 72,450Source | 6,037Source | — |
| DilutedEarningsLossPerShareCAD/shares | -0.65Source | -1.98Source | -1.21Source | — |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesCAD | — | — | — | 880,615Source |
| GeneralAndAdministrativeExpenseCAD | 264,009Source | 278,809Source | 478,248Source | 197,125Source |
| IncomeTaxExpenseContinuingOperationsCAD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseOnLeaseLiabilitiesCAD | 8,945Source | 19,750Source | 2,173Source | — |
| ProfessionalFeesExpenseCAD | 547,765Source | 437,679Source | 650,196Source | 709,954Source |
| ResearchAndDevelopmentExpenseCAD | 1,180,010Source | 4,999,944Source | 12,180,938Source | 6,313,988Source |
| RevenueFromInterestCAD | 30,133Source | — | — | — |
Filing attachments
ex991-20260526.htm · 6-K · 2026-05-28
FOR IMMEDIATE RELEASE Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference New York City - May 26, 2026 - Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Hea…
Read attachment ↗ex991-final.htm · 6-K · 2026-01-08
BRIGHT MINDS BIOSCIENCES ANNOUNCES PRICING OF UPSIZED US$175 MILLION PUBLIC OFFERING OF COMMON STOCK New York City, January 7, 2026 - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the “Offering”). In connection with the Off…
Read attachment ↗ex991-20260106launch.htm · 6-K · 2026-01-07
BRIGHT MINDS BIOSCIENCES ANNOUNCES LAUNCH OF US$100 MILLION PUBLIC OFFERING New York City, January 6, 2026 - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in the capital of the Company (the “Common Shares”) and, in lieu of Common Shares to investors that so choose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Common Shares, for aggregate gross proceeds of US$100 million (the “O…
Read attachment ↗ex991-drugnr.htm · 6-K · 2026-01-06
For Immediate Release Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) · BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability o Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 o DEE: 63.3% median reduction in major motor seizures · REM sleep improvement in patients wi…
Read attachment ↗ex991-20260105.htm · 6-K · 2026-01-05
For Immediate Release Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Conference Call and Live Webcast at 8AM ET - - NEW YORK CITY and VANCOUVER, British Columbia, January 5, 2026 - Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for…
Read attachment ↗